Thermo Fisher Scientific (TMO) Stock Rose While Chilton Capital Management Has Lifted Stake by $328,716; As Orbotech LTD (ORBK) Stock Value Declined, Omni Partners Llp Trimmed Its Position by $1.96 Million

Orbotech Ltd. (NASDAQ:ORBK) Logo

Chilton Capital Management Llc increased its stake in Thermo Fisher Scientific Inc (TMO) by 2.95% based on its latest 2018Q2 regulatory filing with the SEC. Chilton Capital Management Llc bought 1,588 shares as the company’s stock rose 10.49% with the market. The institutional investor held 55,437 shares of the industrial machinery and components company at the end of 2018Q2, valued at $11.48 million, up from 53,849 at the end of the previous reported quarter. Chilton Capital Management Llc who had been investing in Thermo Fisher Scientific Inc for a number of months, seems to be bullish on the $94.95B market cap company. The stock decreased 2.55% or $6.18 during the last trading session, reaching $235.86. About 1.56M shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 23.20% since December 8, 2017 and is uptrending. It has outperformed by 7.58% the S&P500. Some Historical TMO News: 16/03/2018 – Thermo Fisher Scientific Acquires lntegenX, Provider of Leading Rapid DNA Technology for Human Identification; 16/03/2018 – Thermo Fisher Statement on IntegenX Purchase Doesn’t Include Deal Price; 13/04/2018 – Global Gas Analyzer Market Forecast to 2023 with ABB Group, Emerson Electric, General Electric, Figaro Engineering, and Thermo Fishers Scientific Dominating – ResearchAndMarkets.com; 08/03/2018 Thermo Scientific Krios G3i Cryo-Electron Microscope Announced as 2018 Edison Awards Finalist; 18/05/2018 – BARD1 LIFE SCIENCES LTD – ENTERED INTO AN ASSAY DEVELOPMENT AGREEMENT WITH THERMO FISHER SCIENTIFIC; 12/04/2018 – Thermo Scientific Krios G3i Cryo-Electron Microscope Wins Gold Edison Award; 01/05/2018 – SPECTRUM, THERMO FISHER IN DIAGNOSTIC PARTNERSHIP; 23/04/2018 – Thermo Fisher Scientific Inc expected to post earnings of $2.40 a share – Earnings Preview; 16/04/2018 – Thermo Fisher Scientific Launches Oncomine Childhood Cancer Research Assay and Establishes International Childhood Oncology Net; 25/04/2018 – Thermo Fisher: Currency Translation Increased 1Q Revenue by 4%

Omni Partners Llp decreased its stake in Orbotech Ltd (ORBK) by 6.69% based on its latest 2018Q2 regulatory filing with the SEC. Omni Partners Llp sold 32,134 shares as the company’s stock declined 6.11% while stock markets rallied. The hedge fund held 448,229 shares of the industrial machinery and components company at the end of 2018Q2, valued at $27.70M, down from 480,363 at the end of the previous reported quarter. Omni Partners Llp who had been investing in Orbotech Ltd for a number of months, seems to be less bullish one the $2.82B market cap company. The stock decreased 1.91% or $1.13 during the last trading session, reaching $58.11. About 231,846 shares traded. Orbotech Ltd. (NASDAQ:ORBK) has risen 44.03% since December 8, 2017 and is uptrending. It has outperformed by 28.41% the S&P500. Some Historical ORBK News: 08/05/2018 – Orbotech 1Q Rev $250.6M; 19/03/2018 – RPT-Chip gear maker KLA-Tencor to buy Orbotech for $3.4 bln; 19/03/2018 – RPT-ORBOTECH LTD – TRANSACTION APPROVED BY BOARD OF DIRECTORS OF KLA-TENCOR, ORBOTECH; 19/03/2018 – M&A News [Reg]: Semiconductor equipment maker KLA-Tencor buys Orbotech to find additional sources of growth; 19/03/2018 – ORBOTECH LTD – KLA-TENCOR INTENDS TO RAISE APPROXIMATELY $1 BLN IN NEW LONG-TERM DEBT FINANCING TO COMPLETE SHARE REPURCHASE; 19/03/2018 – KLA-Tencor Buys Israel’s Orbotech at $3.4 Billion Valuation; 19/03/2018 – KLA-TENCOR ANNOUNCES AGREEMENT TO ACQUIRE ORBOTECH LTD; 16/05/2018 – Orbotech and the Institute of Microelectronics (IME) to Develop Advanced Packaging Solutions in Fan-Out Wafer Level Packaging J; 19/03/2018 – KLA-Tencor Sees Orbotech Deal Immediately Adding to Adjusted EPS/; 19/03/2018 – ORBOTECH LTD – KLA-TENCOR’S $2 BLN SHARE REPURCHASE PROGRAM IS TARGETED TO BE COMPLETED WITHIN 12 TO 18 MONTHS FOLLOWING CLOSE OF TRANSACTION

More notable recent Thermo Fisher Scientific Inc. (NYSE:TMO) news were published by: Nasdaq.com which released: “Investor Expectations to Drive Momentum within Diversified Restaurant, Perion Network, Bluegreen Vacations, Lantronix, Thermo Fisher Scientific, and The Joint — Discovering Underlying Factors of Influence – Nasdaq” on November 13, 2018, also Seekingalpha.com with their article: “Emerson Electric Is A Great Industrial Stock – Cramer’s Lightning Round (11/8/18) – Seeking Alpha” published on November 09, 2018, Seekingalpha.com published: “Arena Pharmaceuticals Is Speculative – Cramer’s Lightning Round (11/15/18) – Seeking Alpha” on November 16, 2018. More interesting news about Thermo Fisher Scientific Inc. (NYSE:TMO) were released by: Gurufocus.com and their article: “IDEXX Clear Leader in Animal Diagnostics, but Market Growth Could Boost Others – GuruFocus.com” published on November 16, 2018 as well as Seekingalpha.com‘s news article titled: “Thermo Fisher in-licenses CRISPR technologies – Seeking Alpha” with publication date: September 18, 2018.

Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 16 have Buy rating, 0 Sell and 3 Hold. Therefore 84% are positive. Thermo Fisher Scientific had 72 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Buy” rating by Barclays Capital on Monday, September 25. The rating was maintained by Cowen & Co on Wednesday, October 25 with “Buy”. Morgan Stanley maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Thursday, February 1. Morgan Stanley has “Overweight” rating and $227 target. The firm has “Neutral” rating by Cleveland given on Friday, September 9. The firm earned “Buy” rating on Monday, October 23 by Robert W. Baird. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, January 31 report. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Neutral” rating given on Thursday, October 18 by Cleveland. Jefferies maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Tuesday, August 22. Jefferies has “Hold” rating and $195.0 target. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Overweight” rating given on Thursday, February 1 by Barclays Capital. The firm earned “Buy” rating on Thursday, July 20 by Cleveland.

Chilton Capital Management Llc, which manages about $1.18B and $1.05B US Long portfolio, decreased its stake in Facebook Inc (NASDAQ:FB) by 1,980 shares to 88,166 shares, valued at $17.13M in 2018Q2, according to the filing. It also reduced its holding in Bank Amer Corp (NYSE:BAC) by 23,569 shares in the quarter, leaving it with 260,409 shares, and cut its stake in Johnson & Johnson (NYSE:JNJ).

Investors sentiment increased to 1.08 in 2018 Q2. Its up 0.22, from 0.86 in 2018Q1. It improved, as 43 investors sold TMO shares while 378 reduced holdings. 100 funds opened positions while 356 raised stakes. 332.19 million shares or 0.06% more from 331.98 million shares in 2018Q1 were reported. Hills Bank & Trust holds 1.04% or 17,364 shares. Manufacturers Life Insurance The, Ontario – Canada-based fund reported 1.04M shares. Select Equity Gru Inc Lp stated it has 0% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Retirement Of Alabama owns 398,181 shares or 0.4% of their US portfolio. Tower Rech Ltd Liability (Trc) has invested 0.1% in Thermo Fisher Scientific Inc. (NYSE:TMO). Amica Retiree Medical reported 0.53% stake. Western Asset owns 0% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 1 shares. Intact Inv Incorporated accumulated 2,000 shares or 0.01% of the stock. Archford Strategies Limited Liability Com owns 6,072 shares for 0.44% of their portfolio. Hemenway Co Limited Co holds 0.14% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO) for 3,654 shares. First Manhattan Communication has 508,815 shares for 0.61% of their portfolio. Guinness Asset Management Limited stated it has 0% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Middleton & Company Ma accumulated 10,873 shares. Johnson Fincl Group Inc Inc stated it has 623 shares or 0.01% of all its holdings. Hartford Inv Mngmt Company stated it has 0.33% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO).

Since June 13, 2018, it had 0 insider purchases, and 5 sales for $57.02 million activity. Shares for $4.26 million were sold by Herrema Gregory J.. Jacks Tyler sold $1.14 million worth of stock or 4,772 shares.

Analysts await Orbotech Ltd. (NASDAQ:ORBK) to report earnings on February, 13. They expect $0.80 earnings per share, down 2.44% or $0.02 from last year’s $0.82 per share. ORBK’s profit will be $38.85 million for 18.16 P/E if the $0.80 EPS becomes a reality. After $0.73 actual earnings per share reported by Orbotech Ltd. for the previous quarter, Wall Street now forecasts 9.59% EPS growth.

Omni Partners Llp, which manages about $1.06 billion and $883.90M US Long portfolio, upped its stake in Nxstage Medical Inc (NASDAQ:NXTM) by 96,612 shares to 482,831 shares, valued at $13.47M in 2018Q2, according to the filing. It also increased its holding in Express Scripts Hldg Co (NASDAQ:ESRX) by 50,664 shares in the quarter, for a total of 281,026 shares, and has risen its stake in Amtrust Finl Svcs Inc (NASDAQ:AFSI).

Among 10 analysts covering Orbotech (NASDAQ:ORBK), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Orbotech had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 11 by Jefferies. The stock of Orbotech Ltd. (NASDAQ:ORBK) has “Buy” rating given on Thursday, August 10 by Oppenheimer. Jefferies maintained the stock with “Buy” rating in Monday, July 10 report. The rating was maintained by Needham on Monday, November 16 with “Buy”. Jefferies maintained the stock with “Buy” rating in Wednesday, August 2 report. Oppenheimer maintained the stock with “Buy” rating in Thursday, February 15 report. Jefferies maintained it with “Buy” rating and $58.0 target in Monday, February 12 report. Oppenheimer maintained it with “Buy” rating and $4200 target in Thursday, August 3 report. The firm has “Outperform” rating given on Tuesday, January 5 by Cowen & Co. Barclays Capital maintained the stock with “Overweight” rating in Thursday, November 2 report.

More notable recent Orbotech Ltd. (NASDAQ:ORBK) news were published by: Nasdaq.com which released: “Friday’s ETF with Unusual Volume: IDEV – Nasdaq” on November 16, 2018, also Streetinsider.com with their article: “KLA-Tencor (KLAC) to Acquire Orbotech (ORBK) in $3.4 Billion Deal – StreetInsider.com” published on March 19, 2018, Nasdaq.com published: “ORBK Crosses Above Key Moving Average Level – Nasdaq” on December 03, 2018. More interesting news about Orbotech Ltd. (NASDAQ:ORBK) were released by: Streetinsider.com and their article: “Qualcomm says China comment will not revive NXP deal – StreetInsider.com” published on December 03, 2018 as well as Nasdaq.com‘s news article titled: “Validea Motley Fool Strategy Daily Upgrade Report – 11/30/2018 – Nasdaq” with publication date: November 30, 2018.

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.